{"title":"研究人员发现，OTC纳洛酮的吸收有限","authors":"Alison Knopf","doi":"10.1002/adaw.34674","DOIUrl":null,"url":null,"abstract":"<p>The Food and Drug Administration approved over-the-counter (OTC) naloxone more than two years ago, but uptake has been limited, according to research published online September 15 in <i>JAMA Internal Medicine</i>. The research, from RAND, found that the peak in sales was immediately after approval, and decreased rapidly through August of 2024 when it stabilized. The purpose of the approval was to make the opioid reversal drug more accessible.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 38","pages":"7-8"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Researchers find limited uptake on OTC naloxone\",\"authors\":\"Alison Knopf\",\"doi\":\"10.1002/adaw.34674\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The Food and Drug Administration approved over-the-counter (OTC) naloxone more than two years ago, but uptake has been limited, according to research published online September 15 in <i>JAMA Internal Medicine</i>. The research, from RAND, found that the peak in sales was immediately after approval, and decreased rapidly through August of 2024 when it stabilized. The purpose of the approval was to make the opioid reversal drug more accessible.</p>\",\"PeriodicalId\":100073,\"journal\":{\"name\":\"Alcoholism & Drug Abuse Weekly\",\"volume\":\"37 38\",\"pages\":\"7-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alcoholism & Drug Abuse Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34674\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alcoholism & Drug Abuse Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34674","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Food and Drug Administration approved over-the-counter (OTC) naloxone more than two years ago, but uptake has been limited, according to research published online September 15 in JAMA Internal Medicine. The research, from RAND, found that the peak in sales was immediately after approval, and decreased rapidly through August of 2024 when it stabilized. The purpose of the approval was to make the opioid reversal drug more accessible.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
